Author:
Mielke Johanna,Innerbichler Franz,Schiestl Martin,Ballarini Nicolas M.,Jones Byron
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies. Drugs. 2011;71:1527–36.
2. FDA. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. Available at
http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
. Accessed 03 Feb 2017.
3. FDA. FDA withdraws draft guidance for industry: statistical approaches to evaluate analytical similarity. 2018. Available at
https://www.fda.gov/Drugs/DrugSafety/ucm611398.htm
. Accessed 17 July 2018.
4. Tsong Y, Dong X, Shen M. Development of statistical methods for analytical similarity assessment. J Biopharm Stat. 2017;27:197–205.
5. Burdick RK, Thomas N, Cheng A. Statistical considerations in demonstrating CMC analytical similarity for a biosimilar product. Stat Biopharm Res. 2017;9:249–57.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献